For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…
Assessing the health secretary's biggest challenges, and a look at new rules that inject politics into the NIH.
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.
Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
An Ebola update, Trump to strip job protections of NIH officials, and more health news from Morning Rounds
Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.
Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them as diligent note-takers for patients.
“One of the cancer community’s worst fears is coming to pass,” writes Gwen Nichols of Blood Cancer United.
Due to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.
Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found
A brief hantavirus update, some good news about death, and more health news from Morning Rounds
Many adults are sharing device data with providers too. But users are typically healthier and wealthier, suggesting people who could benefit the most from health monitoring are less likely to adopt the tools, according to Rock Health.
An acquisition of Independence would further expand West Virginia University Health System into southwestern Pennsylvania.
Rising costs are eroding Americans’ trust in their commercial plans despite an industry-wide push to increase consumer satisfaction, the analytics firm found.
Ardent elevated its former COO, Dave Caspers, to the top job as the Tennessee-based system grapples with its declining stock price.
Nearly three-quarters of clinicians said losing critical thinking or decision-making skills will be one of the greatest risks of adopting artificial intelligence, according to a survey by Wolters Kluwer Health.
Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.
The state claims UnitedHealthcare inflated the sickness of seniors enrolled in MassHealth managed care plans to reap at least $100 million in improper payments.
An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.
Among the affected positions, which the White House estimates to be 8,000, are high-level officials who oversee research grants from the NIH.
Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
The advanced model should support earlier and more accurate diagnoses and treatment planning, the companies said.
Ascension needs to sell seven surgery centers if it wants the deal to close, regulators said. Ascension, which is pursuing the AmSurg acquisition as part of a larger financial turnaround, said it was pleased with the compromise.
Got a story, tip, or tool worth covering? People and agents can submit it here. Approved items appear in the feed and newsletter.
One concise email a day — the headlines that matter in health & wellness. No noise.
Free. Unsubscribe anytime.